Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: Efficacy, safety, and hepatocyte growth factor and O6-methylguanine-DNA methyltransferase biomarker analyses

Journal of Clinical Oncology

Volumn 35, Issue 3, 2017, Pages 343-351

  Cloughesy, Timothy ^a   Finocchiaro, Gaetano ^e   Belda Iniesta, Cristóbal ^g   Recht, Lawrence ^b   Brandes, Alba A ^f   Pineda, Estela ^h   Mikkelsen, Tom ^d   Chinot, Olivier L ^j   Balana, Carmen ⁱ   Macdonald, David R ^k   Westphal, Manfred ^l   Hopkins, Kirsten ^m   Weller, Michael ⁿ   Bais, Carlos ^c   Sandmann, Thomas ^c   Bruey, Jean Marie ^c   Koeppen, Hartmut ^c   Liu, Bo ^c   Verret, Wendy ^c   Phan, See Chun ^c   Shames, David S ^c   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c GENENTECH INC   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f Azienda USL di Bologna   (Italy)

^g Hospital Universitario HM Sanchinarro   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^j AIX MARSEILLE UNIVERSITY   (France)

^k LONDON HEALTH SCIENCES CENTRE   (Canada)

^l UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^m BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; ONARTUZUMAB; PLACEBO; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DNA LIGASE; DNA METHYLTRANSFERASE; HGF PROTEIN, HUMAN; MGMT PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADULT; ARTICLE; ASTHENIA; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; DNA METHYLATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; GLIOBLASTOMA; HEADACHE; HGF GENE; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOALBUMINEMIA; INFECTION; INFESTATION; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MALE; MGMT GENE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; ONCOGENE; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; TREATMENT RESPONSE; VASCULAR DISEASE; BRAIN NEOPLASMS; CLINICAL TRIAL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR RECURRENCE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; DISEASE-FREE SURVIVAL; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; DOUBLE-BLIND METHOD; FEMALE; GLIOBLASTOMA; HEPATOCYTE GROWTH FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 85010063077     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.64.7685     Document Type: Article

References (30)

1. Ostrom QT, Gittleman H, Liao P, et al: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol 16(Suppl 4):iv1-iv63, 2014
2. Walker C, Baborie A, Crooks D, et al: Biology, genetics and imaging of glial cell tumours. Br J Radiol 84:S90-S106, 2011
3. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996, 2005
4. Weller M, van den Bent M, Hopkins K, et al: EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 15:e395-e403, 2014
5. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98-110, 2010
6. Chaudhry IH, O'Donovan DG, Brenchley PEC, et al: Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39:409-415, 2001
7. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009
8. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009
9. Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007
10. Soffietti R, Trevisan E, Bertero L, et al: Bevacizumab and fotemustine for recurrent glioblastoma: A phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 116:533-541, 2014
11. Maree K, Simes J, Wheeler H, et al: A randomized phase II study of carboplatin and bevacizumab in recurrent glioblastoma multiforme (CABARET). Presented at the 2013 American Society of Clinical Oncology Annual Meeting, Chicago, IL, USA, May 31-June 4, 2013
12. Taal W, Oosterkamp HM, Walenkamp AM, et al: Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): A randomised controlled phase 2 trial. Lancet Oncol 15:943-953, 2014
13. Desjardins A, Reardon DA, Coan A, et al: Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302-1312, 2012
14. Chinot OL, Wick W, Mason W, et al: Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014
15. Gilbert MR, Dignam JJ, Armstrong TS, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699-708, 2014
16. Sandmann T, Bourgon R, Garcia J, et al: Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: Retrospective analysis of the AVAglio trial. J Clin Oncol 33:2735-44, 2015
17. Blumenschein GR Jr, Mills GB, Gonzalez- Angulo AM: Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 30:3287-3296, 2012
18. Lu KV, Bergers G: Mechanisms of evasive resistance to anti-VEGF therapy in glioblastoma. CNS Oncol 2:49-65, 2013
19. Kulig K, McLendon RE, Locke SC, et al: MET and ALK in glioblastoma multiforme (GBM): Comparison of IHC and FISH. J Clin Oncol 30, 2012 (suppl; abstr 2021)
20. Koochekpour S, Jeffers M, Rulong S, et al: Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res 57:5391-5398, 1997
21. Xie Q, Bradley R, Kang L, et al: Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci USA 109:570-575, 2012
22. Garnett J, Chumbalkar V, Vaillant B, et al: Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 15:73-84, 2013
23. Martens T, Schmidt NO, Eckerich C, et al: A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 12:6144-6152, 2006
24. Wen PY, Macdonald DR, Reardon DA, et al: Updated response assessment criteria for high-grade gliomas: Response Assessment in Neuro-Oncology Working Group. J Clin Oncol 28:1963-1972, 2010
25. Koeppen H, Yu W, Zha J, et al: Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib6onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 20:4488-4498, 2014
26. Weller M, Stupp R, Reifenberger G, et al: MGMT promoter methylation in malignant gliomas: Ready for personalized medicine? Nat Rev Neurol 6:39-51, 2010
27. Cankovic M, Mikkelsen T, Rosenblum ML, et al: A simplified laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fixed paraffin-embedded tissue. Lab Invest 87:392-397, 2007
28. Weller M, Cloughesy T, Perry JR, et al: Standards of care for treatment of recurrent glioblastoma - Are we there yet? Neuro-oncol 15:4-27, 2013
29. Hack SP, Bruey JM, Koeppen H: HGF/MET-directed therapeutics in gastroesophageal cancer: A review of clinical and biomarker development. Oncotarget 5:2866-2880, 2014
30. Goyal L, Muzumdar MD, Zhu AX: Targeting the HGF/c-MET pathway in hepatocellular carcinoma. Clin Cancer Res 19:2310-2318, 2013